• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD

How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD

April 5, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Patient Monitoring, Research & Development, Technology, Wall Street Beat Tagged With: BD, embecta

BD completes spinoff of Embecta diabetes company

April 1, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

BD (NYSE:BDX) announced today that the planned spinoff of its diabetes business — named Embecta (Nasdaq:EMBC)— has been made official. Franklin Lakes, New Jersey-based BD announced its intention to spinoff the diabetes business in May 2021. Near the end of 2021, it unveiled the soon-to-be independent, publicly-traded company’s name as “Embecta,” with plans to complete the spinoff during […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Wall Street Beat Tagged With: BD, embecta

BD provides Embecta spinoff update, plans for April 1 completion

March 21, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

BD (NYSE:BDX) announced today that it still expects the spinoff of its diabetes business — named Embecta — to complete on April 1. Franklin Lakes, N.J.–based BD announced in May 2021 that it intended to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: BD, embecta

Many infusion pumps are vulnerable to hackers, study says

March 3, 2022 By Sean Whooley

Hacker altumcode

Palo Alto Network’s Unit 42 released results from a study showing that 75% of infusion pumps observed had known cybersecurity gaps. The results involved crowdsourced data from scans of more than 200,000 infusion pumps on the network of health providers using IoT Security for Healthcare from Palo Alto Networks. Vulnerabilities observed in the study included […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured Tagged With: BD, Cybersecurity, infusion pump, infusion systems

BD board approves Embecta diabetes business spinoff

February 1, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

BD (NYSE:BDX) announced today that its board of directors approved the planned spinoff of its diabetes care business, Embecta. Franklin Lakes, N.J.-based BD confirmed in May 2021 that it planned to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it confirmed the […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Initial Public Offering (IPO), Wall Street Beat Tagged With: BD, embecta

12 of medtech’s biggest personnel changes in 2021

December 17, 2021 By Sean Whooley

Medtech personnel changes

As medtech companies continued to drive innovation throughout the past 12 months, a number of high-level executives led the way. Some of those companies and those executives opted for major changes over the course of 2021, though, with some high-profile moves from medtech giant to medtech giant. Here are some of the biggest personnel moves […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Personnel Tagged With: abbott, BD, Dexcom, embecta, Medtronic, Personnel, Personnel Moves

BD chooses ’embecta’ as new name for Diabetes Care spinoff, confirms leadership team

December 6, 2021 By Sean Whooley

BD Diabetes Spinoff Embecta

BD (NYSE:BDX) announced today that it named its Diabetes Care business — which it plans to spin off next year — “embecta.” Franklin Lakes, New Jersey-based BD confirmed in May that it plans to spin off its Diabetes Care business as an independent, publicly-traded company during the first half of 2022 and confirmed today that […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: BD, embecta, Personnel, Personnel Moves

BD breaks ground on pre-filled syringe manufacturing plant in Spain

November 16, 2021 By Sean Whooley

BD

BD (NYSE:BDX) announced today that it broke ground on its $200 million pre-filled drug delivery device manufacturing plant in Spain. Franklin Lakes, New Jersey-based BD announced in May that it would build the $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, with expectations of creating up to 600 jobs at the facility by 2030. […]

Filed Under: Auto-injectors, Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD

BD ticks up on Street-beating Q4, sets 2022 guidance range

November 4, 2021 By Sean Whooley

BD

BD (NYSE:BDX) shares rose today on fourth-quarter results that came in ahead of the consensus forecast. The Franklin Lakes, New Jersey-based medtech posted profits of $242 million, or 84¢ per share, on sales of $5.1 billion for the three months ended Sept. 30, 2021, more than doubling its bottom line on sales growth of 7.3%. Get […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: BD, coronavirus, COVID-19

New BD syringe manufacturing lines are up and running in Nebraska

October 7, 2021 By Sean Whooley

BD

BD (NYSE:BDX) announced today that it increased its manufacturing capacity and domestic supply for syringes and needles. Franklin Lakes, N.J.-based BD’s new syringe and needle manufacturing lines, which were completed on an accelerated timeline, represent BD’s partnership with Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR). In July 2020, […]

Filed Under: Auto-injectors, Business/Financial News, Contract Services, Drug-Device Combinations, Featured Tagged With: BARDA, BD, Becton Dickinson, coronavirus, COVID-19, HHS

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS